Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Naia
Cayman Islandsnaia.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NB1001, a long‑acting GLP‑1 agonist using XTEN technology, demonstrated efficacy and up to a month-long half-life in a clinical study for SBS and received orphan drug designation. The company’s pipeline includes additional GLP-based therapies and small molecules targeting rare GI and metabolic diseases
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Peptide (GLP receptor agonists)Small molecule (for metabolic disease program NC101)
- Industry
- Biotech
02
Partnerships
Amunix Operating Inc.Pharco PharmaceuticalsCedars-Sinai Medical Center
Beyond the preview
Go deeper on Naia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Naia.